ArticleCentral-European journal of immunology2025
Inhibition of XPOT promotes breast cancer cell pyroptosis to suppress cancer progression.
Article in Central-European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer (BC) remains a significant threat to women's health, necessitating the identification of new targets to inhibit its progression. Pyroptosis, a form of programmed cell death characterized by cellular swelling, distortion, and increased inflammatory factors, has emerged as a potential mechanism. High expression of exportin-T (XPOT) is linked to poor prognosis in BC patients, but its role in BC progression is not well understood. Material and methods: We used the GEPIA database to analyze XPOT expression in BC and confirmed XPOT levels in BC tissues via immunohistochemistry. Western blotting was used to assess XPOT expression in various BC cell lines. We transfected small interfering RNAs (siRNAs) targeting XPOT and verified the transfection efficiency using Western blotting. The impact of si-XPOT on MCF-7 cell proliferation and apoptosis was measured using CCK-8 and TdT-mediated dUTP nick-end labeling assays. Scratch and Transwell assays were used to evaluate cell metastasis. Enzyme-linked immunosorbent assay was used to measure pyroptosis-associated inflammatory factors interleukin (IL)-1β and IL-18. Western blotting was used to detect pyroptosis-related proteins gasdermin D (GSDMD) and inflammasome components. Results: XPOT expression was elevated in BC tissues, with higher levels in MCF-7 cells compared to other BC cells. Silencing XPOT reduced MCF-7 cell viability, migration, and invasion. Inhibition of XPOT increased pyroptosis-associated inflammatory factors, elevated N-terminal shear levels of GSDMD, and upregulated NLRP3, ASC, and cleaved-caspase1 expression. The pyroptosis inhibitor azalamellarin N reversed the effects induced by si-XPOT. Conclusions: Silencing XPOT promotes pyroptosis in BC cells and inhibits BC progression, suggesting that targeting XPOT could offer new therapeutic avenues for BC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.